2. Recent News  Salarius Pharmaceuticals to Host Virtual Key Opinion Leader and Investor Event  Salarius Pharmaceuticals Announces New Clinical Trial to Study Seclidemstat in Hematologic Cancers  Salarius Pharmaceuticals to Host Virtual Key Opinion Leader and Investor Event  Salarius Pharmaceuticals Presents New Research Data Demonstrating Seclidemstat ’ s Safety, Dosing, and Drug Activity at American Society of Clinical Oncology (ASCO) 2021 Annual Meeting  Salarius Pharmaceuticals Discloses Key Findings from Three Abstracts to be Presented at American Society of Clinical Oncology (ASCO) 2021 Annual Meeting  Salarius Pharmaceuticals Reports First Quarter Financial Results with Business Highlights  Salarius Pharmaceuticals Announces Titles of Three Abstracts Accepted for Poster Presentations at American Society of Clinical Oncology 2021 Annual Meeting  Salarius Pharmaceuticals Announces Acceptance of Three Abstracts for Poster Presentations at the 2021 American Society of Clinical Oncology Annual Meeting  Salarius Pharmaceuticals Reports Business Highlights with Fourth Quarter and Full - Year 2020 Financial Results  Salarius Announces Closing of $23 Million Underwritten Public Offering of Common Stock Following Full Exercise of Over - Allotment Option  Salarius Pharmaceuticals to Present at the Diamond Equity Research Emerging Growth Invitational Virtual Conference  Salarius Completes Dose - Escalation Stage of Phase 1/2 Clinical Trial in Relapsed and Refractory Ewing Sarcoma Patients, Initiates Expansion Stage in Ewing and Ewing - Related Sarcoma Patients  Salarius Pharmaceuticals Initiates Expansion Stage of Phase 1/2 Clinical Trial of Seclidemstat in Patients with Ewing Sarcoma and Ewing - Related Sarcomas Management David J. Arthur — C hief Executive Officer Mr. Arthur is a senior life sciences executive with 25+ years of US and global experience building and leading medical and marketing organizations in product development; launching and managing pharmaceutical and device brands. Prior to accepting the role as Chief Executive Officer Salarius Pharmaceuticals, David was Managing Director Dacon Pharma, LLC. Additionally, David spent 20+ years with Eli Lilly and Boehringer - Ingelheim in executive roles managing product development, business development, US business, global commercialization, European regional marketing and financial planning/analysis. Mr. Arthur earned a BS in Chemical Engineering from North Carolina State University, a Masters of Business Administration from the Duke University Fuqua School of Business, is a licensed Professional Engineer and Six Sigma Green Belt. Mark J. Rosenblum, CPA — Chief Financial Officer Mr. Rosenblum is an accomplished financial executive with over 30 years senior management experience within the healthcare and chemical manufacturing industries. Prior to joining Salarius, Mr. Rosenblum served as Chairman, Chief Executive Officer and Director of ActiveCare as well as the Chief Financial Officer of Advaxis. Mr. Rosenblum was employed by Wellman for nearly 20 years, which was later acquired by DAK Americas, serving in various capacities including Chief Accounting Officer. Mr. Rosenblum began his career with Haskins & Sells, CPA (currently known as Deloitte), was a licensed Certified Public Accountant for over 30 years and is currently a member of the American Institute of Certified Public Accountants. Mr. Rosenblum holds both a Masters in Accountancy and a B.S. degree in Accounting from the University of South Carolina. Nadeem Q. Mirza, MD, MPH — Senior Vice President, Clinical Development Over the past 16 years, Dr. Mirza has brought his clinical development and medical affairs expertise to multiple companies and development opportunities in the oncology space, spanning emerging to globally established companies and early - stage to commercial - stage drug programs. Prior to joining Salarius, Dr. Mirza served as Chief Medical Advisor at TRIGR Therapeutics, Inc. and before that as Senior Vice President, Corporate Medical Affairs at Verastem Oncology, where he oversaw the launch of Copiktra®, an oral medication for relapsed or refractory chronic lymphocytic leukemia and follicular lymphoma. Previously, Dr. Mirza held senior positions at several major biopharmaceutical companies and participated in launch activities for seven other cancer and leukemia medications, including Campath®, Abraxane®, Nexavar®, Clolar®, Zaltrap®, Jevtana®, and Venclexta®. He served as Global Head Hematology and Solid Tumors at AbbVie Oncology and Vice President, Head of Oncology, North America Medical Affairs at Sanofi Oncology. Dr. Mirza also held leadership roles in medical affairs and clinical development at Genzyme/Sanofi, Onyx Pharmaceuticals, Inc., Abraxis Oncology, and Berlex Oncology. www.salariuspharma.com

3. Disclaimer Notice: The information contained in this e - mail message and its attachments is intended solely for the use of the indi- vidual(s) to whom it is addressed and may contain information that is the confidential information of Acorn Management Partners L.L.C. ("AMP") and its subsidiaries. The Information may be about companies in which A.M.P has or may receive compensation in the future. Any material in this message should be considered as ADVERTISMENT ONLY . Please consult with a certified finan- cial advisor before making any investment decisions. All information on this report should be confirmed before making an inve st- ment decision. Acorn Management Partners L.L.C. ("AMP") and its subsidiaries, and any affiliates and information providers m ake no implied or express warranties on the information provided. This is not to be construed as a solicitation to buy or sell se cur ities. As with any stock, the featured companies involve a high degree of risk and volatility, and all investors/advisors should know t hat they may lose a portion or all of their investment if they decide to purchase any stock. Acorn Management Partners L.L.C. ("AMP") , i ts affiliates, associates, relatives and anyone associated with in any manner reserves the right to either buy or sell shares in th e profiled company's stock. The Securities and Exchange Commission has compiled an extensive amount of information concerning investing, including the inherent risks involved. We encourage our readers to visit the SEC's website to acquire this important information. Safe Harb or Dis- closure: Acorn Management Partners L.L.C. ("AMP") website publications may contain or incorporate by reference "forward - looking statements, including certain information with respect to plans and strategies of the featured company. As such, any sta te- ments contained herein or incorporated herein by reference that are not statements of historical fact may be deemed to be for war d - looking statements. Without limiting the forgoing, the words "believe(s)," "anticipate(s)," "plan(s)," "expect(s)," "project( s)" and similar expressions are intended to identify forward - looking statements. There are a number of important factors that could caus e actual events or actual results of the Companies profiled herein to differ materially from these indicated by such forward - looki ng statements. Certain statements contained herein constitute forward - looking statements within the meaning of Section 27A of the S e- curities Act of 1933 and 21E of the Exchange Act of 1934. Such statements include, without limitation, statements regarding b usi- ness and financing, business trends, future operating revenues and expenses. Statements relating to the overall ability of ep ige netic regulator drugs to correct gene changes in disease and its ability to successfully initiate and complete clinical trials and reg ulatory submissions; Seclidemstat ’ s impact in Ewing sarcoma and as a potential new and less toxic treament; expected dose escalation and dose expansion; expected therapeutic options for SP - 2577 and related effects and projected efficacy, including SP2577 ’ s ability to inhibit LSD1. Although the Company believes that the statements are reasonable, it can give no assurances that such expectations will prove to be correct. Investors are cautioned that any forward looking statements made by the Company, or contained in any and/or all prof ile / research reports, contain no guarantee of future performance, and that the actual result may differ materially from those set fo rth in the forward - looking statements. Difference in results can be caused by various factors including, but not limited to, the Compan y's ability to be able to successfully complete planned funding agreements, to successfully market its products in competitive in dus tries or to effectively implement its business plan or strategies. Any statements that express or involve discussions with respect to predic- tions, expectations, beliefs, plans, projections, objectives, goals, assumptions, or future events or performance are not sta tem ents of historical fact and may be "forward looking statements." Forward looking statements are based on expectations, estimates, and pr o- jections at the time the statements are made that involve a number of risks and uncertainties which could cause actual result s o r events to differ materially from those presently anticipated. Forward looking statements in this action may be identified thr oug h the use of words such as "expects," "will," "anticipates," "estimates," "believes," "may," or by statements indicating certain ac tio ns "may," "could," or "might" occur. We encourage our readers to invest carefully and review all forms of investments and read t he investor information. More information please visit http://www.sec.gov and/or (FINRA) at: http://www.FINRA.com. Readers can review all public filings by companies at the SEC's EDGAR page. The FINRA has published information on how to invest carefull y at its web site. “ Full Market Awareness ” A Professional Relations Company And Consulting Firm 678 - 736 - 5685 Contact: Brandon Bouysou Brandon@AcornManagementPartners.com Atlanta, Georgia Sarasota, Florida

1. A C O R N M A N A G E M E N T P A R T N E R S , L L C Pharmaceuticals Epigenetics For More Information “ Call AMP ” Brandon Bouysou 678 - 736 - 5685 salariuspharma.com Salarius Pharmaceuticals (NCM: SLRX) is an emerging biotechnology company developing targeted therapies to treat pediatric and other cancers, including advanced solid tumors. The lead compound Seclidemstat represents a potential paradigm shift in the treatment of cancer and we are initially targeting Ewing sarcoma, a devastating pediatric, adolescent and young adult bone cancer where no targeted therapies are currently available. Seclidemstat Salarius' lead molecule, Seclidemstat, is an oral reversible LSD1 inhibitor. Seclidemstat offers a viable therapeutic option for patients who need it the most. Seclidemstat has demonstrated the ability to reverse cancer pathology resulting in cures in animal models. Salarius began a Ewing Sarcoma Phase 1/2 trial in 2018 and began a second Phase 1/2 trial enrolling advanced solid tumors patients in 2019. This trial is enrolling patients with advanced solid tumors who have progressed on prior therapy, for example, patients with prostate, breast, ovarian, lung and other sarcomas. On December 16, 2019, Seclidemstat received FDA Fast Track Designation. Development Pipeline Company Highlights  Market Opportunity — Multi - billion dollar market potential with possible accelerated approval, priority review eligibility ($100M value), and orphan drug designation.  Leading Product — Seclidemstat, is a novel, oral, best - in - class, reversible LSD1 inhibitor in clinical development with safety and efficacy data expected in 2021; received FDA Fast Track Designation in December 2019; Salarius recently announced that it has completed the dose - escalation stage and established the recommended Phase 2 dose (RP2D) for its ongoing Phase 1/2 clinical trial in relapsed/refractory (R/R) Ewing sarcoma.  Investor Leverage — Recipient of over $18M in non - dilutive financing, including CPRIT award.  Future Expansion — Potential for multiple combination therapy options; Immuno - oncology demonstrated in vitro/in vivo; Identifying tumor mutations that confer sensitivity.  Competitive Landscape — Novel epigenetic drugs with clinical proof of concept support billion - dollar valuations (including EPZM and CNST).  Experienced Leadership — The Salarius team exhibits extensive industry experience and skilled organizational leaders proficient in business development and growth. AMP Quick Facts Salarius Pharmaceuticals (NCM:SLRX) J U L Y 2 0 2 1 NCM: SLRX Price: $1.02 7/6/21 Fiscal Yr: 12/31 Market Cap: $45.7M Cash on Hand: $37M Previous Raise: $23M Revenue: $5.23M Shares Out: 44.8mm Float: 26.2mm Avg. Volume: 1.38m Employees: 15